Isoprostanes: More than just mere markers

被引:17
作者
Crankshaw, DJ
Rangachari, PK
机构
[1] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada
[2] McMaster Univ, Dept Obstet & Gynecol, Honours Biol Pharmacol Coop Program, Hamilton, ON L8N 3Z5, Canada
关键词
isoprostanes; oxidant injury; pathophysiology; biological effects; mechanism of action; prostanoid receptors;
D O I
10.1023/A:1026052123843
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Isoprostanes are members of a family of prostaglandin isomers that are produced by free radical-catalysed mechanisms. They have become well-recognized indicators of oxidant-induced cell damage in a variety of pathophysiological conditions. Several isoprostanes have been shown to possess biological activity in whole-animal, isolated tissue and cell-based systems. Their actions include vasoconstriction, platelet aggregation and cardiac hypertrophy. Current evidence suggests that these effects are mediated by prostanoid receptors through a complex set of interactions that involve agonism, partial agonism, desensitization and co-operative behaviors. It is likely that other mechanisms of action are waiting to be discovered. Based on a consideration of these biological effects, we argue that isoprostanes are more than mere markers and may serve as active participants in promoting and exaggerating pathophysiological changes. To tease out their roles requires considerable more work and a willingness to suspend disbelief based on limited evidence.
引用
收藏
页码:125 / 130
页数:6
相关论文
共 56 条
  • [1] ALEXANDER SPH, 2001, SCI 2001 S, V12, P85
  • [2] Cardiovascular responses to the isoprostanes iPF2α-III and iPE2-III are mediated via the thromboxane A2 receptor in vivo
    Audoly, LP
    Rocca, B
    Fabre, JE
    Koller, BH
    Thomas, D
    Loeb, AL
    Coffman, TM
    FitzGerald, GA
    [J]. CIRCULATION, 2000, 101 (24) : 2833 - 2840
  • [3] EFFECTS OF A NOVEL PROSTAGLANDIN, 8-EPI-PGF2-ALPHA, IN RABBIT LUNG INSITU
    BANERJEE, M
    KANG, KH
    MORROW, JD
    ROBERTS, LJ
    NEWMAN, JH
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 263 (03): : H660 - H663
  • [4] Metabolism of 8-iso-prostaglandin F2α
    Basu, S
    [J]. FEBS LETTERS, 1998, 428 (1-2) : 32 - 36
  • [5] Specific analysis in plasma and urine of 2,3-dinor-5,6-dihydro-isoprostane F2α-III, a metabolite of isoprostane F2α-III and an oxidation product of γ-linolenic acid
    Burke, A
    Lawson, JA
    Meagher, EA
    Rokach, J
    FitzGerald, GA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (04) : 2499 - 2504
  • [6] Identification and measurement of endogenous β-oxidation metabolites of 8-epi-prostaglandin F2α
    Chiabrando, C
    Valagussa, A
    Rivalta, C
    Durand, T
    Guy, A
    Zuccato, E
    Villa, P
    Rossi, JC
    Fanelli, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (03) : 1313 - 1319
  • [7] COLEMAN RA, 1994, PHARMACOL REV, V46, P205
  • [8] Human internal mammary artery contraction by isoprostaglandin F2α type-III (8-iso-prostaglandin F2α)
    Cracowski, JL
    Stanke-Labesque, F
    Devillier, P
    Chavanon, O
    Hunt, M
    Souvignet, C
    Bessard, G
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 397 (01) : 161 - 168
  • [9] Response of rat thoracic aorta to F2-isoprostane metabolites
    Cracowski, JL
    Camus, L
    Durand, T
    Devillier, P
    Guy, A
    Hardy, G
    Stanke-Labesque, F
    Rossi, JC
    Bessard, G
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2002, 39 (03) : 396 - 403
  • [10] Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications
    Cracowski, JL
    Durand, T
    Bessard, G
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (08) : 360 - 366